Short answer
Neurogene Inc. (NGNE) filed its Q3 2026 10-Q quarterly report on Nov 9, 2026 for the quarter ended Sep 30, 2026.
Q3 2026 key financials · XBRL
- Net income
- −$29M
- −38.5% YoY · +15.8% QoQ
- EPS (diluted)
- −$0.98
- +1.0% YoY · +35.9% QoQ
Source: XBRL data from the Neurogene Inc. (NGNE) Q3 2026 10-Q on SEC EDGAR. USD.
Neurogene Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- No product revenue, unchanged from prior-year quarter; net loss $29.0M vs $21.0M YoY
- Operating margin not applicable, operating loss $32.4M vs $23.8M YoY
- Rett syndrome program largest expense, $8.9M vs $5.6M YoY
- Cash, equivalents and short-term investments $359.7M; operating cash use $79.0M nine-month period
- July offering raised $134.9M; runway extended into first quarter of 2029, topline NGN-401 data expected second half 2027
Risk Factors
- Newly emphasized regulatory risk: FDA denied NGN-101’s RMAT designation, removing the streamlined registrational pathway and potentially ending further investment
- Most material clinical update: NGN-401’s 3E15 vg dose was removed after a November 2024 fatal SAE, with additional safety monitoring added
- Operational risk: NGN-401 remains dependent on successful Embolden trial execution after dosing completion in the second quarter of 2026
- Financial risk: $447.1 million cumulative net loss, with existing cash expected to fund operations into the first quarter of 2029
- Supply-chain risk: U.S. tariffs and BIOSECURE Act restrictions could disrupt Chinese biotechnology relationships and increase material costs
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Neurogene Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.